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Infectious and inflammatory diseases are a heterogeneous
class of diseases encompassing many different clinical con-
ditions and may be classified into infection, acute inflam-
mation, and chronic inflammation. These diseases can affect
multiple organs (systemic) or can be localized in one specific
organ and are often relapsing and invalidating and may
require life-long treatment [1].
Clinicians often struggle with questions in patients deal-
ing with presumed or established infectious and inflamma-
tory disorders. Often they are not well-recognized and when
recognized many questions remain: Is there an infectious
focus or an inflammatory sign? What are the size and the
extent of the lesion? Is this the only lesion in the body or
are there infectious metastases? When can the treatment be
stopped or should it be switched or continued?
It is very important for the clinician to distinguish
between an infection and sterile inflammation. If possible, it
may lead to major changes in the treatment of the patients.
The recent progress in our understanding and knowledge of
the pathophysiology of many infectious and inflammatory
diseases has led to the development of several new and spe-
cific radiopharmaceuticals in order to meet clinical demand
[2–4]. We also learned that, with some radiopharmaceuti-
cals, the lack of specificity can be overcome by applying a
particular imaging acquisition protocol (as it is for white-
blood-cell scan in prosthetic joint infections) [5] or by using
combination of two radiopharmaceuticals (as it is for imaging
diabetic foot infection in patients with Charcot joint) [6].
Nowadays, the goal is to identify the type of the disease
and the cells and mediators that are involved in the process
[7–10].
Diagnosis and characterization of the infectious or
inflammatory processes are most often performed with
conventional radiology and biochemical tests. Radiologi-
cal techniques show anatomical changes. These changes,
however, usually occur in a late and chronic stage of the
disease, thereby leading to a delayed diagnosis and therapy.
Nuclear medicine imaging techniques detect biological and
biochemical changes in the earliest phase of the diseases,
thereby allowing the clinician not only to promptly identify
the infective or inflammatory focus but also to establish the
best therapeutic approach for patients.The recent availability
ofmany innovativemolecules, such asmonoclonal antibodies
and analogues of growth and signaling factors, offers to
nuclear medicine physicians a wide spectrum of promising
radiopharmaceuticals as markers for different pathological
events.
The development of hybrid camera techniques, such as
PET/CT and SPECT/CT, led to a new area of imaging, in
which the best of both anatomical and pathophysiological
techniques are combined, leading to higher specificities and
diagnostic accuracies [11]. The very recent development of
combined PET/MRI camera systems may bring this diag-
nostic accuracy to an even higher level, especially in inflam-
matory cases, since MRI offers better soft tissue contrast
information than CT [12].
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This special issue consists of both invited review articles
and original research papers from experts from all over the
world in the booming field of infectious and inflammatory
diseases.The focus of this special issue is to highlight existing
imaging techniques and their current position in specific
infectious and inflammatory diseases, to share new possi-
bilities in new hybrid camera systems, to identify common
patterns for nuclear medicine and radiological diagnosis of
infectious and inflammatory diseases, to present new cellular
and animal models for preclinical research, and to share the
development and testing of novel radiopharmaceuticals in the
field.
Infection and Inflammation of the Cardiovascular System.
Diagnosing infections and inflammation of the cardiovas-
cular system is a rapidly growing area in which nuclear
medicine techniques play an important role. Several papers
on this topic are published in this special issue dealing with
vasculitis, vascular prosthetic graft infection, atherosclerosis,
and endocarditis.
H. Balink et al. present an overviewof the use of 18F-FDG-
PET/CT in large vessel vasculitis. They claim that there is a
substantial under diagnosis of large vessel vasculitis and that
18F-FDG-PET/CT may shed a new light on the classification
of giant cell arteritis and Takayasu arteritis, thereby strength-
ening the idea that both diseases aremore likely to be different
expressions of a common histopathological entity.
C. Puppo et al. provide a systematic review including
19 original articles with a total of 442 patients with giant
cell arteritis. They describe all the different qualitative, semi-
quantitative, and combinedmethods that have been proposed
for assessing the presence and grading of the severity of the
vascular inflammation. Qualitative methods are less sensitive
butmore specific than semiquantitativemethods. Among the
semiquantitative approaches, the aortic-to-blood pool uptake
ratio of the aortic arch seems to be themost accuratemethod.
K. J. Lensen et al. evaluated several qualitative/visual
analysis methods in this setting and looked at the best inter-
observer agreement between six nuclear medicine physicians
of both academic and peripheral/general hospitals. They
found the highest interobserver agreement when vascular
wall 18F-FDG uptake higher than liver uptake was used as
a diagnostic criterion. Agreement was also good without
predefined methods, the so-called first impression. They
highlighted that standardization of image assessment pro-
motes interobserver agreement.
The paper by B. R. Saleem et al. deals with the same
problem of which interpretation criterion should be used
but this time in vascular prosthetic graft infections (VPGI).
No clear guidelines exist on this area and the interpretation
by a visual grading scale is considered to be too subjective.
Based on literature they suggest that a linear, diffuse, and
homogeneous uptake should not be regarded as an infection,
whereas focal or heterogeneous uptake with a projection over
the vessel on CT is highly suggestive of infection.
To the opinion of the guest editors, 18F-FDG-PET/CT
should routinely be used in the imaging of vasculitis and in
vascular graft infection, both for diagnosis and for therapy
evaluation. Of course it is of invaluable importance that we
all follow the same procedures in acquisition protocols and
interpretation criteria tomake comparison between literature
results possible and to start multicenter prospective trials to
finally make this technique a new standard in diagnostic and
therapy evaluating flow charts.
R. S. Ripa and A. Kjaer share with us the initial experi-
ences with simultaneous PET/MRI for atherosclerosis imag-
ing. They give a short summary of current relevant clinical
applications of PET and MRI in the setting of atherosclerosis
and discuss future potential vascular applications exploiting
the unique combination of PET and MRI.
M. Musso and N. Petrosillo performed a review of the lit-
erature to assess the available evidence on the role of nuclear
medicine techniques in the diagnosis of prosthetic valve
endocarditis. Both 18F-FDG-PET/CT and 99mTc-HMPAO
labelledwhite blood cells with SPECT/CThave demonstrated
to be effective imaging methods that maybe can be used to
increase the sensitivity of the Duke criteria and can identify
important complications in the course of prosthetic valve
endocarditis, including perivalvular abscesses and metastatic
septic embolization.
Sarcoidosis. Sarcoidosis is a granulomatous disease that
usually affects multiple organs. The presence of cardiac
involvement is associated with adverse events such as heart
failure, arrhythmias and sudden cardiac death, and an overall
poor outcome. Early diagnosis and treatment is critically
important.Therefore, M. Orii et al. provide us an overview of
the epidemiology, etiology, histological findings, and clinical
features of sarcoidosis. In this paper, they introduce advanced
imaging methods including 18F-FDG-PET and cardiac MRI
as reliable diagnostic modalities for cardiac sarcoidosis. Hep-
atosplenic involvement of sarcoidosis often shows a benign
course but portal hypertension and loss of liver function
may occur. Therefore, a correct evaluation of these organs
represents an important step in patients with sarcoidosis.The
role of conventional imaging, such as CT and MRI in the
assessment of hepatosplenic sarcoidosis, is well-established,
by revealing organ enlargement, multiple discrete nodules,
and lymphadenopathy. C. Tana et al. describe in their review
contrast-enhanced ultrasound findings in liver and spleen
involvement and share with us evidence from the literature
and cases from their own experience.
Preclinical Research. Preclinical research is of invaluable
importance to continue look for new radiopharmaceuticals
and better use of existing radiopharmaceuticals to improve
the diagnostic possibilities. J. C. E. Odekerken et al. focused
on the longitudinal assessment of a nonimplant related
osteomyelitis by introducing an intramedullary tibial infec-
tion with S. aureus in NZW rabbits. The development of
the infection was assessed by microPET at consecutive time
points using 18F-FDG as an infection tracer. Indeed, the
intramedullary contamination of the rabbit tibia resulted in
osteomyelitis, so osteomyelitis in the rabbit can be induced
without the use of an implant or sclerosing agent as was used
in earlier studies. From all parameters used, the diagnostic
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value of 18F-FDG micro PET was the most versatile to assess
the presence of an orthopaedic infection in this animal
model.
D. M. Chandrupatla et al. made modifications in a rat
model of rheumatoid arthritis (RA) to widen the thera-
peutic window for PET-guided evaluation of novel anti-
RA agents. They induced arthritis in the right knee of
Wistar rats and gave, after immunization, one or more intra-
articular methylated bovine serum albumin injections over
time in the right knee. Besides many other analyses, they
found increased 18F-FDG and 11C-PK11195 accumulation in
arthritic knees as compared to contralateral normal knees,
which was confirmed in ex vivo tissue distribution studies.
Thismodel will offer excellent opportunities for repeated PET
studies tomonitor progression of disease and efficacy of novel
therapeutic agents for RA in the same animal.
Antimicrobial peptides are a heterogeneous class of com-
pounds found in a variety of organisms including humans.
The ability of these peptides to accumulate at sites of infection
combined with the minimal host’s cytotoxicity makes these
peptides potential radiopharmaceuticals to allownoninvasive
whole-body examination for detection of occult infection. An
overview of all the existing peptides and the strategy, design,
and utilization of these peptides is given by T. Ebenhan et al.
B. Mokaleng et al. report TBIA101, an antimicrobial pep-
tide derivate that was conjugated to DOTA and radiolabelled
with 68Ga for an in vitro and in vivo infection imaging
using Escherischia coli-bearing mice by targeting bacte-
rial lipopolysaccharides with PET/CT. 68Ga-DOTA-TBIA101-
PET detected E. coli-infected muscle tissue > noninfected
thighs > forearm muscles > background in the same animal.
Normalization of the infected thighmuscle to reference tissue
showed a ratio of 3.0 ± 0.8 compared to a ratio of 2.3 ± 0.6
in the identical healthy tissue.These findings warrant further
preclinical imaging studies of greater depth.
Tailored Radiopharmaceuticals.Nuclear medicine techniques
may play a crucial role by providing objective biomarkers
for personalized medicine.These techniques offer the unique
possibility to target cells and molecules that are involved for
histological characterization, selection of patients for targeted
therapy, therapy response prediction, and therapy response
follow-up. Research in this field must be encouraged and
supported.
The paper from F. Galli et al. is a nice example of this
important concept. Recently, the use of anti-tumor necrosis
factor alpha (anti-TNF𝛼) agents has been introduced for
therapy of chronic and refractory sarcoidosis with contro-
versial results. Therefore, 99mTc-labelled infliximab was used
to study the expression of TNF𝛼 in sarcoid lesions and
to evaluate its role as a predictive marker of response to
therapy. The results were, however, slightly disappointing.
A low correlation was found between target-to-background
ratios and BAL results in patients that were despite positive
at 18F-FDG-PET. The authors concluded that in this study
10 patients had a low presence of TNF𝛼. The concept that
this anti-TNF𝛼 scintigraphy is a good tool for the selection of
patients to be treated with anti-TNF𝛼 drugs is an important
one since our techniques can reveal if this expensive therapy
will be successful in the individual patient. So maybe the 10
patients scanned should not be treatedwith anti-TNF𝛼drugs;
however, to conclude this further investigation is warranted.
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